Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01HVZ
|
|||
Former ID |
DNCL001947
|
|||
Drug Name |
TD-8954
|
|||
Synonyms |
TD-8954; UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Gastrointestinal disease [ICD-11: DE2Z] | Phase 2 | [1] | |
Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1/2 | [2], [3] | ||
Company |
Theravance
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C25H37N5O3
|
|||
Canonical SMILES |
CC(C)C1=NC2=C(C=CC=C2N1)C(=O)NCC3CCN(CC3)CC4CCN(CC4)C(=O)OC
|
|||
InChI |
1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
|
|||
InChIKey |
MZOITCJKGUIQEI-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 916075-84-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 4 receptor (HTR4) | Target Info | Modulator | [4] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Serotonergic synapse | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
5HT4 type receptor mediated signaling pathway | ||||
Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | |||
Reactome | Serotonin receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03827655) A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery. U.S. National Institutes of Health. | |||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8426). | |||
REF 3 | ClinicalTrials.gov (NCT01953081) A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance. U.S. National Institutes of Health. | |||
REF 4 | The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.